David Kao, MBA

Vice President, Regulatory Affairs

Professional Overview
David Kao is a seasoned regulatory affairs executive with over 25 years of experience in the pharmaceutical and biopharmaceutical industries. As the Vice President of Regulatory Affairs at Inhibrx, Inc., he leverages his deep expertise in navigating complex global regulatory landscapes to drive the successful development and commercialization of innovative therapeutics.

Experience Summary

Current Role
As Vice President of Regulatory Affairs at Inhibrx, Inc., David is responsible for leading the company's regulatory strategy and execution across all development programs. He collaborates closely with cross-functional teams to ensure timely and compliant regulatory submissions, manage interactions with global health authorities, and support the advancement of Inhibrx's growing pipeline of novel biologic and small molecule therapeutics.

Career Progression
Prior to joining Inhibrx, David held various leadership roles in regulatory affairs at prominent pharmaceutical companies, including Bristol Myers Squibb, Receptos (a wholly-owned subsidiary of Celgene), Daiichi Sankyo, Roche Pharmaceuticals, Eisai, Merck, and SmithKline Beecham. Throughout his career, he has demonstrated a track record of successfully navigating complex regulatory environments, securing key approvals, and contributing to the advancement of therapies across multiple therapeutic areas, including immunology, oncology, and neuroscience.

Academic Background
David holds a Master of Business Administration (MBA) degree from the University of Southern California, Marshall School of Business, and a Bachelor of Science in Pharmacy from the University of Illinois at Chicago.

Areas of Expertise

• Global regulatory strategy and execution

• Regulatory submissions and interactions with health authorities

• Clinical development program management

• Cross-functional collaboration and leadership

• Therapeutic area expertise in immunology, oncology, and neuroscience

Professional Impact
During his tenure, David has made significant contributions to the development and approval of several novel therapeutics, including biologics and small molecules. His work has helped to bring life-changing treatments to patients in need and advance the overall state of healthcare. David's industry expertise, strategic thinking, and collaborative approach have earned him a reputation as a trusted regulatory affairs leader.

Conclusion
With his deep regulatory expertise, strong leadership skills, and a proven track record of success, David Kao is well-positioned to drive the regulatory strategy and contribute to the continued growth and success of Inhibrx, Inc. as the company advances its innovative pipeline of biotherapeutics.